A Glimpse of Zhongguancun Life Science Park
Zhongguancun Life Science Park, as an important support for the main platform of Beijing International Technology Innovation Center” consisting of Zhongguancun Science City, Huairou Science City, Changping Future Science City as well as Yizhuang Economic and Technological Development Zone, is a highland for the development of pharmaceutical and health industry that integrates four state-level functional zones, that is, Zhongguancun Independent Innovation Demonstration Zone, National Comprehensive Demonstration Zone for the Expansion and Opening-up of the Service Industry, Free Trade Pilot Zone, and the core area of high-level talents in Beijing. After 20 years of development, the Park has attracted multiple state-level research and development institutions to have their presence here, brought together a group of globally top scientists and hundreds of high-level talents. There are more than 600 innovative pharmaceutical enterprises and over 300 high-end talents, including 21 academicians, 4 scholars supported by the Cheung Kong Scholars Programme, 50+ personnel entitled to special allowance from the State Council, 7 academician workstations, 20+ post-doctoral research centers, 10+ national engineering research centers and key laboratories, 16 R&D centers at provincial and ministerial level, and nearly 3,000 sickbeds in the medical institutions, thus forming the trend of bringing together the whole industry chain including basic research, R&D pilot test, production and circulation, and terminal healthcare. It has been built into one of the parks with the most concentrated innovation resources in the field of life science in China, which is an innovation engine for the development of the pharmaceutical and health industry in Beijing.
300 +
High-end talents
600 +
Innovative pharmaceutical enterprises
7 +
Academician workstations
21 +
Post-doctoral research centers
10 +
Academician workstations
16
R&D centers at provincial and ministerial level
INDUSTRYGROUP
INNOVATIONPLATFORM
Beijing Zhongguancun Life Science Park Biomedicine Technology Incubation Co., Ltd. is a professional incubator specializing in the field of biomedicine. Since its establishment, it has received dozens of licensing and qualifications granted by the government. In addition, it undertakes work related to Overseas Students Pioneer Park at Beijing Zhongguancun Life Science Park and the IPR Public Service Workstation at Changping District Life Science Park, offering incubation service for more than 140 well-known startup companies in the industry, such as BeiGene, Crown Bioscience, BerryGenomics, Novogene, Sironax, Biocytogen, MyGenostics, etc.
The international incubator ATLATL, a high-end platform for the acceleration of innovation projects, which aligns with the standards of top international biopharmaceutical R&D centers, initiated by Dr. Zhu Pengcheng, focusing on key subdivisions and emerging technology fields such as cell and gene therapy, miRNA, gene editing and synthetic biology. By introducing professional research teams, it aims to build a base for double transformation in international cooperation on cutting-edge technology and the industrialization of R&D results. Recently, ATLATL, together with SEQUANTA, has set up a sequencing center to better serve customers and contribute to more unicorn companies in Beijing.
Bio2, built and officially put into operation in 2021, focusing on the needs of scientists and entrepreneurs, puts emphasis on the transformation of early results in life and health and business incubation. Relying on the combined advantages of “professional carrier platform + abundant funding channels + active interactive information base”, Bio2 provides start-up teams with ready-to-use shared office space and professional shared experimental sites. At present, nearly 30 potential projects with global leading technologies have been reserved, and 44 innovation-oriented enterprises such as Sironax, Neural Galaxy, Shuimu Biosciences, Pulmongene Ltd., and Simcere have settled here.
Changping Life Valley Marathon Digital Medical Incubator is China’s first digital medical business incubator jointly initiated by BC-TID, Zhongguancun Life Science Park and Marathon Venture Partners. With the vision of making investment for accelerating the new generation of digital medical entrepreneurs and promoting global digital medical industry-university-research innovation, the incubator will focus on the development direction of digital healthcare and smart healthcare, such as AI healthcare, medical robot, genomics, digital therapy, insurance technology, committed to making full cooperation with the world’s top parks, medical centers, scientific research institutions and other ecological partners.
2024-11-21
倒计时1天!2024北京·昌平生命科学论坛诚邀莅临
倒计时1天!2024国际药物研发论坛参会指南抢先看
《药海共潮 创新共舞——自然合作会议:2024国际药物研发论坛暨中关村生命科学园发展论坛》将于 2024年11月22日 如期举办。为了让您有个愉快的参会经历,请阅读以下参会指南: 会议时间 2024年11月22日 会议地点 北京市昌平区九华山庄会展酒店(16区)三层101、102室 会议签到 时间:2024年11月22日 10:00开始签到 地点:北京市昌平区九华山庄会展酒店(16区)三层102、...
企业资讯丨图湃医疗与Mainline合作,正式开启英国与爱尔兰市场
近日,中关村生命科学园内企业 图湃医疗 宣布与Mainline Instruments Ltd建立合作伙伴关系 旨在将图湃尖端的10-40万速全域扫频源OCT/OCTA技术带给该地区的眼科医生 预计阅读时间:2分钟 Mainline董事总经理杰克·霍金斯(左)与图湃医疗国际事务副总周健(右)在图湃医疗上海中心签署战略合作协议 Mainline Instruments成立于1997年总部设立于英国伯...
企业资讯丨质肽生物创新型口服GLP-1多肽即将开展I期首次人体临床试验
11月7日,中关村生命科学园内企业 质肽生物 自主研发的 ,获得国家药品监督管理局药品审评中心(CDE)临床试验默示许可, 。 预计阅读时间:2分钟 图源:国家药品监督管理局药品审评中心 目前市场获批肥胖适应症的GLP-1 受体激动剂均依赖于传统的皮下注射。 。 此外,口服制剂药品使用保存方便,没有额外设备需求,可以显著提高患者的便利性。 目前全球范围内尚无口服GLP-1RA类产品获批体重管理适应...